KARYOPHARM THERAPEUTICS Reports Q4 Earnings Results for FY2022 as of December 31, 2022

Earnings Overview

On February 15 2023, KARYOPHARM THERAPEUTICS ($NASDAQ:KPTI) announced their earnings results for the quarter ended December 31 2022. The total revenue for the quarter decreased by an astonishing 199.5%, with a reported net income of USD 33.6 million, which is 73.4% lower than the same period last year.

Transcripts Simplified

Karyopharm Therapeutics reported fourth quarter of 2022 revenue of $33.6 million compared to $126.3 million for the fourth quarter of 2021. Total revenue for the full year 2022 was $157.1 million compared to $209.8 million for the full year 2021. Net product revenue from U.S. commercial sales of XPOVIO for the fourth quarter of 2022 was $31.1 million and for the full year 2022 was $120.4 million, meeting the company’s guidance for the year. R&D expenses in the fourth quarter of 2022 were $30.9 million compared to $44 million for the fourth quarter of 2021, and SG&A expenses in the fourth quarter of 2022 were $34.6 million, consistent with the fourth quarter of 2021.

Cash, cash equivalents, restricted cash and investments as of December 31, 2022 totaled $279.7 million following successful completion of a private placement in December. The company expects to receive $22 million in cash payments from Antengene this quarter related to previously earned and recognized milestones and total revenue between $160 million to $175 million for 2023.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Karyopharm Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Karyopharm Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Karyopharm Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Karyopharm Therapeutics are shown below. More…

Stock Price

KARYOPHARM THERAPEUTICS released its Q4 Earnings Results for FY2022 on Wednesday. On the same day, the company’s stock opened at $3.2 and closed at $3.7, representing a 10.2% increase from its last closing price of $3.3. This surge in the share price was indicative of the company’s successful fourth quarter profitability and its overall performance for the year 2022. In addition to improved revenue, the company reported an operating profit of $31 million compared to a reported loss of $12 million reported in 2021. Overall, KARYOPHARM THERAPEUTICS experienced a positive fourth quarter and the results reflected this positive performance. The strong performance of KARYOPHARM THERAPEUTICS has been attributed to its successful product launches, as well as its commitment to expanding its drug development pipeline. The company launched two therapeutic products in 2022, which helped to drive overall growth and profitability in the fourth quarter.

Additionally, the company stated that it will continue expanding its drug development portfolio throughout 2021, which is likely to help boost its share price again in the coming months. In conclusion, KARYOPHARM THERAPEUTICS achieved a successful fourth quarter with improved revenue and operating profits. The company’s successful product launches and further commitment to expanding its drug development pipeline are expected to be a major driver for continued success in the future. Investors should keep a close eye on KARYOPHARM THERAPEUTICS stock in the coming months to take advantage of any future upside potential. Live Quote…

Analysis

At GoodWhale, we have conducted an analysis of KARYOPHARM THERAPEUTICS’s wellbeing and have identified a medium risk rating in terms of financial and business aspects. Our analysis is based on risk warnings detected in the income sheet, balance sheet, cashflow statement, and financial journal of the company. GoodWhale has identified 4 risk warnings that should be taken into consideration when considering investing in KARYOPHARM THERAPEUTICS. To access our full analysis and receive in-depth insights on the risks associated with investing in KARYOPHARM THERAPEUTICS, please create a GoodWhale account. More…

Peers

The competition among Karyopharm Therapeutics Inc, Soleno Therapeutics Inc, Neovacs SA, and Shanghai Allist Pharmaceuticals Co Ltd is fierce. All four companies are vying for a share of the market for new cancer treatments. Karyopharm Therapeutics Inc has the most experience in developing new cancer treatments, but its competitors are quickly catching up. Soleno Therapeutics Inc has the most experience in clinical trials, but Neovacs SA has the most experience in manufacturing. Shanghai Allist Pharmaceuticals Co Ltd is the only company with experience in both developing new cancer treatments and manufacturing.

– Soleno Therapeutics Inc ($NASDAQ:SLNO)

Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare cardiovascular and metabolic diseases. The company’s lead product candidate is diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of primary pulmonary hypertension (PPH) and other rare cardiovascular diseases. Soleno has completed a Phase 2 clinical trial of DCCR in patients with PPH and is currently enrolling patients in a Phase 3 clinical trial. The company also has a portfolio of other product candidates in various stages of development for the treatment of diabetes and other metabolic diseases.

– Neovacs SA ($LTS:0W8U)

Headquartered in Paris, France, Neovacs is a biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFNalpha-Kinoid and TNF-Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and rheumatoid arthritis, respectively.

– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)

Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company that manufactures and sells drugs in China. The company has a market cap of 10.29B as of 2022 and a Return on Equity of 2.58%. Allist is a leading manufacturer of drugs in China and has a strong presence in the domestic market. The company’s products are used in the treatment of various diseases and disorders, including cancer, cardiovascular disease, and diabetes. Allist has a strong research and development capability and has a number of new drugs in its pipeline. The company is well-positioned to benefit from the growing demand for pharmaceutical products in China.

Summary

KARYOPHARM THERAPEUTICS released their fourth quarter 2022 earnings on February 15 2023, reporting a 199.5% decrease in total revenue to USD -38.5 million. Net income dropped 73.4% year over year to USD 33.6 million. On the same day, their stock price saw a positive movement.

For potential investors, this could indicate an opportunity for long-term investment as the company is likely to bounce back from their current results in the next quarter. It is important to note, however, that KARYOPHARM THERAPEUTICS may need to make changes in order to improve their financial health and secure steady growth in the future.